An interventional study of Mechanical nasal dilator in Nasal Obstruction, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-18.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment
Among 65 studies in Nasal Obstruction with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Nasal Obstruction · United States.
Among the 65 studies in Nasal Obstruction with a site in United States, this one is the 39th largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2018, is one of 34 with no phase, and was the 34th registered.
173 studies on the registry are indexed under Nasal Obstruction; 31 are open to participants now.
Browse Nasal Obstruction studies →9 of the 65 studies in Nasal Obstruction with a site in United States are open now. Recruiting first, the newest first:
Aerin Medical · Sites in United States
Ages 22–85
Washington University School of Medicine · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–70 · Healthy volunteers
University of Michigan · Sites in United States
Ages 3–21
Endeavor Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Nasal Obstruction studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 8 · Phase 4 4
First in 2005; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 70 across 139 interventional studies indexed under Nasal Obstruction.
Median enrollment 51 across the 56 interventional studies, 40 across the 9 observational. Of the 50 that completed or were terminated, 27 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 65 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 314 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 1 study filed under Nasal Obstruction — fewer than ten, so there is no comparison to draw.
7 of the studies in Nasal Obstruction with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04194216Phase 3Stanford UniversityAntibiotic Prophylaxis in Rhinoplasty | 2026-12-20 |
| NCT06830109Washington University School of MedicineNasal Obstruction With Oxymetazoline and Corticosteroids | 2026-12-30 |
| NCT06163404Spirair, IncOpen-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant | 2027-03 |
| NCT07574918Aerin MedicalMeasuring Nasal Airway Changes After VivAer Treatment Using AI Analysis | 2027-05 |
| NCT05527652University of MichiganSelf-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 65 studies in Nasal Obstruction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The research team has developed a prototype for an investigational mechanical nasal dilator and the investigators aim to evaluate its efficacy.
Specifically, the investigators wish to address the following research questions: 1) How does mechanical nasal obstruction affect patients' lives? The investigators aim to answer this question with use of validated questionnaires. 2) How do currently available mechanical nasal dilators affect objective and subjective findings related to nasal obstruction? This will be evaluated with objective nasal airflow testing and with modifications to validated questionnaires 3) How does the investigational team's novel device affect these same outcome measures? 4) Do patients find the investigational device subjectively comfortable and efficient?
Background:
Restricted nasal breathing is a common complaint among patients presenting to Otolaryngology clinics. In fact, one in eight people experiences some degree of nasal obstruction, or regular difficulty breathing through the nose, which is often the result of a narrowing or collapse of the internal nasal valve. This condition is a daily source of discomfort that reduces productivity and quality of life. Sufferers report shortness of breath throughout the day, difficulty sleeping and habitual snoring, and limited stamina during sports and exercise.
Slight dilation of the nasal passages directly counteracts nasal obstruction and reverses symptoms in 89% of those afflicted. To this end, many patients undergo functional rhinoplasty procedures to surgically widen the nasal passages. However, up to 20% of patients experience unimproved or worsened symptoms postoperatively. Moreover, these surgeries are invasive, requiring autologous grafts taken from the nose, ear, or ribs; and surgeries entail a yearlong recovery period.
Nasal dilators such as Breathe Right strips offer a potential alternative to surgery, as these dilators mechanically expand the nasal passages to effectively relieve obstruction. However, existing products are designed as sleep aids, and customers find them uncomfortable, difficult to use, and too visible to wear in public. Although the mechanism for reversing nasal obstruction is straightforward, surgery is considered the only viable option for those who struggle to breathe during the day.
Engineers from the Johns Hopkins Biomedical Engineering Department, partnered with clinicians from the Johns Hopkins Department of Otolaryngology - Head and Neck Surgery, have developed the Schnozzle, a small silicone stent to counteract nasal valve collapse and relieve restricted nasal breathing. The investigators hypothesize that this device will improve symptoms of nasal obstruction and provide patients with a viable alternative to visible non-invasive devices or surgical management. The aim of this study is to evaluate the feasibility and comfort of this device in comparison to existing commercially available devices.
Recruitment:
Participants will be recruited from patients presenting to Otolaryngology clinics with symptoms of nasal obstruction. The otolaryngologist in clinic will screen these patients for nasal valve collapse as in standard clinical practice. This involves visualizing the nasal cavity through nasal endoscopy and evaluating the nasal valve using Cottle maneuver (applying lateral force to the cheek to open the nasal valve) or the modified Cottle maneuver (using a cotton tip applicator to open the nasal valve from inside the nasal cavity) and evaluating for improvement in nasal obstruction symptoms. Improved nasal airflow during the maneuver suggests nasal valve collapse contributes to restricted nasal airflow.
The clinical Otolaryngologist will counsel participants with nasal valve collapse regarding the various treatment options as in routine clinical practice (management options include to doing nothing, using existing nasal dilator devices, or undergoing surgery). Patients will then be invited to participate in the study, which will involve a study session in which patients are fitted with several nasal dilator devices, instructed in proper care and use, and report on their function and comfort. Additional participants will be recruited from patients who present to clinics with symptoms unrelated to nasal breathing to serve as a control group.
Study design:
If a patient expresses interest in participating, the patient will be introduced to a member of the research team to discuss the study and complete informed consent. All participation is voluntary and participants are able to withdraw from the study at any point. The study participant will be asked to complete a questionnaire, which includes the previously validated Nasal Obstruction and Septoplasty Effectiveness (NOSE) instrument, questions regarding the patient's current treatments, and a ranking of their preferred characteristics of an ideal nasal dilator.
Patients will then be asked to inhale rapidly into an airflow transducer to measure peak nasal inspiratory flow (PNIF). Following the pre-test survey participants will be fitted with existing nasal dilator products per manufacturer recommendations (Breathe Right strips, Max Air nose cones, Sleep Right dilator, and Nozovent dilator), and the experimental nasal dilators designed by the research team. In this crossover design study participants will be blinded as to which dilators are branded and which are experimental. The order of fitting nasal dilators will be randomized.
After each fitting and use for 5 minutes to adjust to the device and confirm there is no immediate discomfort or irritation, participants will undergo repeat PNIF testing with each device, then will be free to go home and trial the devices. Participants will be given a schedule specifying one device to use for at least one continuous hour per day in a randomized order, while also being blinded as to which device participants will be using (Schnozzle, Breathe Right, Max Air, Sleep Right, Nozovent). The devices will be numbered in a random fashion, for participants to be able to identify which device via the assigned number the devices are scheduled to use. Participants will similarly use the device number when performing any device evaluation. Participants are free to wear the assigned nasal dilator at their leisure, but must log the hours and activities performed while wearing the device (for example, "10am-11am exercising"). Participants are not required to wear a device in public at work or during exercise unless participants feel comfortable doing so. All devices should be worn overnight. If there is any discomfort, irritation, skin breakdown, or epistaxis the participant should stop wearing the device and contact the research team immediately. Each morning, the participant will complete a survey summarizing their experience using the assigned device. Before returning to the clinic for the conclusion of the study, participants may have several days without an assigned device. Participants are free to stop wearing all devices or use any device as participants please as long as it is consistent with proper care and use of the device(s).
After at least five days (one day per device) the participant will return to the office for an exit interview with the study team in regards to their subjective experience with each device. At the end of each trial participants will be asked to fill out a concluding survey regarding the device participants were using. At their exit interview participants will be asked to hand in the survey for each device participants trialed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
Device: Mechanical nasal dilator
Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
Change in Peak Nasal Inspiratory Flow (PNIF)
PNIF will be measured using a PNIF meter. PNIF will be measured without any device in place and once during the fitting of each device. Flow is measured in liters per minute. Minimum value of -50, maximum value of 150 with higher scores indicating improved airflow.
Time frame: Prior to device and after fitting each device (Up to 5 minutes)
Change in Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE)
The Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE) aims to quantify symptoms of mechanical nasal obstruction. The NOSE metric has a scoring range go 0-100 with 0 being no symptoms of mechanical nasal obstruction and 100 being severe nasal obstruction. Each device is trialed for one day, hence the scale will be administered at Baseline and after a 24-hour trial of each of the 5 devices.
Time frame: Baseline
Change in Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE)
The Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE) aims to quantify symptoms of mechanical nasal obstruction. The NOSE metric has a scoring range go 0-100 with 0 being no symptoms of mechanical nasal obstruction and 100 being severe nasal obstruction. Each device is trialed for one day, hence the scale will be administered at Baseline and after a 24-hour trial of each of the 5 devices.
Time frame: 24-hour after trial of each device
Device Preference
Participants will be asked to rank their preferred device form 1 (most preferred) to 5 (least preferred). The mean will be reported. Scores range from 1-5, with 1 being the most preferred.
Time frame: Up to 5 days
| Milestone | All Participants |
|---|---|
| Started | 36 |
| Completed | 36 |
| Not completed | 0 |
PNIF will be measured using a PNIF meter. PNIF will be measured without any device in place and once during the fitting of each device. Flow is measured in liters per minute. Minimum value of -50, maximum value of 150 with higher scores indicating improved airflow.
| liters per minute | Breathe Right | Max Air | Sleep Right | Mute | Nozovent | Schnozzle |
|---|---|---|---|---|---|---|
| Change in Peak Nasal Inspiratory Flow (PNIF) | 28 ± 42 | 24 ± 38 | 13 ± 20 | 27 ± 47 | 25 ± 35 | 29 ± 40 |
The Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE) aims to quantify symptoms of mechanical nasal obstruction. The NOSE metric has a scoring range go 0-100 with 0 being no symptoms of mechanical nasal obstruction and 100 being severe nasal obstruction. Each device is trialed for one day, hence the scale will be administered at Baseline and after a 24-hour trial of each of the 5 devices.
No measurements were reported for this outcome.
The Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE) aims to quantify symptoms of mechanical nasal obstruction. The NOSE metric has a scoring range go 0-100 with 0 being no symptoms of mechanical nasal obstruction and 100 being severe nasal obstruction. Each device is trialed for one day, hence the scale will be administered at Baseline and after a 24-hour trial of each of the 5 devices.
No measurements were reported for this outcome.
Participants will be asked to rank their preferred device form 1 (most preferred) to 5 (least preferred). The mean will be reported. Scores range from 1-5, with 1 being the most preferred.
| score on a scale | Breathe Rite | Max Air | Sleep Right | Mute | Nozovent Dilator | Schnozzle |
|---|---|---|---|---|---|---|
| Device Preference | 2.9 (1 to 5) | 5 (2 to 5) | 3.8 (1 to 5) | 2.7 (1 to 4) | 2.8 (1 to 4) | 3.8 (1 to 4) |
Collected over Data were collected during device use over a period of 5 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Breathe Right | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Max Air | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Sleep Right | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Mute | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Nozovent | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Schnozzle | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Age, Categorical(Participants) | Mechanical Nasal Dilator |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 29 |
| >=65 years | 6 |
| Age, Continuous(years) | Mechanical Nasal Dilator |
|---|---|
| Median | 52 (17 to 83) |
| Sex: Female, Male(Participants) | Mechanical Nasal Dilator |
|---|---|
| Female | 22 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | Mechanical Nasal Dilator |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 15 |
| Region of Enrollment(Participants) | Mechanical Nasal Dilator |
|---|---|
| United States | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in May 2022, 43 months.
Results were first posted in Jul 2023, 1 year 2 months after primary completion.
Of 39 non-industry interventional studies with no phase under Nasal Obstruction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 43 months is above that.
Counting every sponsor, half of 60 studies reached it within 18 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.